Dois-je éviter minoxidil succinoyl oligopeptide-143 pendant la grossesse ? | VeriMom

What to use instead

Pregnancy-safe ingredients that serve a similar function:

FAQ

minoxidil succinoyl oligopeptide-143 est-il sûr pendant la grossesse ?

Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.

minoxidil succinoyl oligopeptide-143 est-il sûr pendant l'allaitement ?

Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).

minoxidil succinoyl oligopeptide-143 est-il sûr pour la peau de bébé ?

For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.

Comment VeriMom évalue-t-il minoxidil succinoyl oligopeptide-143 ?

VeriMom évalue minoxidil succinoyl oligopeptide-143 à 33/100 (risque élevé) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.

Quelles sont les alternatives sûres à minoxidil succinoyl oligopeptide-143 pendant la grossesse ?

Consultez notre liste d'alternatives sûres à minoxidil succinoyl oligopeptide-143 basée sur une fonction similaire et une classification sans risques connus.